Iterum Retained Earnings vs Total Current Liabilities Analysis

ITRM Stock  USD 1.80  0.18  9.09%   
Iterum Therapeutics financial indicator trend analysis is infinitely more than just investigating Iterum Therapeutics PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iterum Therapeutics PLC is a good investment. Please check the relationship between Iterum Therapeutics Retained Earnings and its Total Current Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Retained Earnings vs Total Current Liabilities

Retained Earnings vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iterum Therapeutics PLC Retained Earnings account and Total Current Liabilities. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Iterum Therapeutics' Retained Earnings and Total Current Liabilities is -0.36. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Iterum Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Iterum Therapeutics' Retained Earnings and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Iterum Therapeutics PLC are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Retained Earnings i.e., Iterum Therapeutics' Retained Earnings and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.36
Relationship DirectionNegative 
Relationship StrengthInsignificant

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Total Current Liabilities

Total Current Liabilities is an item on Iterum Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Iterum Therapeutics PLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Iterum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iterum Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
At this time, Iterum Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 14th of December 2024, Sales General And Administrative To Revenue is likely to grow to 288.20, while Tax Provision is likely to drop about 521.7 K.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation2.1M1.8M1.7M969.1K
Income Tax Expense705K301K613K527.3K

Iterum Therapeutics fundamental ratios Correlations

0.11-0.130.630.58-0.02-0.29-0.090.530.380.270.230.920.580.280.550.860.340.490.270.480.230.50.920.590.33
0.110.52-0.57-0.570.67-0.47-0.16-0.20.530.520.80.00.410.610.250.120.650.560.430.390.820.47-0.010.370.24
-0.130.52-0.71-0.70.57-0.360.72-0.510.80.840.77-0.330.590.330.03-0.140.740.530.790.230.750.52-0.350.090.07
0.63-0.57-0.710.95-0.670.33-0.340.72-0.33-0.4-0.490.71-0.09-0.360.160.5-0.48-0.27-0.25-0.13-0.6-0.170.730.12-0.08
0.58-0.57-0.70.95-0.550.16-0.310.58-0.45-0.52-0.590.72-0.21-0.20.130.55-0.48-0.16-0.280.01-0.59-0.070.740.080.12
-0.020.670.57-0.67-0.55-0.870.28-0.730.40.370.47-0.040.390.870.290.30.770.790.310.760.840.74-0.040.320.69
-0.29-0.47-0.360.330.16-0.87-0.240.46-0.31-0.24-0.26-0.34-0.39-0.97-0.45-0.59-0.76-0.9-0.18-0.96-0.74-0.78-0.32-0.46-0.94
-0.09-0.160.72-0.34-0.310.28-0.24-0.460.560.590.26-0.250.440.07-0.1-0.060.480.370.580.20.340.43-0.26-0.120.08
0.53-0.2-0.510.720.58-0.730.46-0.46-0.06-0.09-0.10.51-0.03-0.40.070.13-0.31-0.3-0.15-0.29-0.38-0.380.490.11-0.33
0.380.530.8-0.33-0.450.4-0.310.56-0.060.990.90.080.890.290.30.180.840.620.80.330.780.580.060.380.02
0.270.520.84-0.4-0.520.37-0.240.59-0.090.990.9-0.030.830.220.190.060.80.550.820.240.760.52-0.060.28-0.06
0.230.80.77-0.49-0.590.47-0.260.26-0.10.90.9-0.050.780.330.330.050.750.530.710.230.820.49-0.070.44-0.05
0.920.0-0.330.710.72-0.04-0.34-0.250.510.08-0.03-0.050.320.340.510.910.190.380.060.480.080.381.00.520.48
0.580.410.59-0.09-0.210.39-0.390.44-0.030.890.830.780.320.350.660.460.760.630.590.460.690.630.310.710.18
0.280.610.33-0.36-0.20.87-0.970.07-0.40.290.220.330.340.350.470.560.740.870.150.920.770.730.320.490.91
0.550.250.030.160.130.29-0.45-0.10.070.30.190.330.510.660.470.590.40.45-0.110.540.370.360.50.990.47
0.860.12-0.140.50.550.3-0.59-0.060.130.180.060.050.910.460.560.590.380.620.160.710.290.670.910.590.67
0.340.650.74-0.48-0.480.77-0.760.48-0.310.840.80.750.190.760.740.40.380.870.620.710.960.750.170.460.52
0.490.560.53-0.27-0.160.79-0.90.37-0.30.620.550.530.380.630.870.450.620.870.480.920.850.930.370.50.75
0.270.430.79-0.25-0.280.31-0.180.58-0.150.80.820.710.060.590.15-0.110.160.620.480.140.590.60.06-0.02-0.07
0.480.390.23-0.130.010.76-0.960.2-0.290.330.240.230.480.460.920.540.710.710.920.140.670.820.460.540.91
0.230.820.75-0.6-0.590.84-0.740.34-0.380.780.760.820.080.690.770.370.290.960.850.590.670.730.060.450.48
0.50.470.52-0.17-0.070.74-0.780.43-0.380.580.520.490.380.630.730.360.670.750.930.60.820.730.380.40.63
0.92-0.01-0.350.730.74-0.04-0.32-0.260.490.06-0.06-0.071.00.310.320.50.910.170.370.060.460.060.380.510.47
0.590.370.090.120.080.32-0.46-0.120.110.380.280.440.520.710.490.990.590.460.5-0.020.540.450.40.510.44
0.330.240.07-0.080.120.69-0.940.08-0.330.02-0.06-0.050.480.180.910.470.670.520.75-0.070.910.480.630.470.44
Click cells to compare fundamentals

Iterum Therapeutics Account Relationship Matchups

Iterum Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets25.8M32.8M91.5M66.8M26.3M24.9M
Other Current Liab3.0M34.3M10.2M6.3M8.5M10.5M
Total Current Liabilities37.0M28.9M6.1M196K13.5M15.0M
Total Stockholder Equity(26.2M)(50.6M)50.2M28.0M(6.4M)(6.1M)
Net Tangible Assets(26.2M)(50.6M)46.8M26.3M23.7M14.9M
Net Debt2.8M21.3M(2.5M)7.4M12.9M13.5M
Retained Earnings(234.9M)(286.9M)(378.5M)(422.9M)(461.3M)(438.2M)
Accounts Payable15.5M816K878K2.8M5.0M3.4M
Cash4.8M14.5M27.4M21.1M6.1M5.8M
Non Current Assets Total21.0M18.3M10.2M6.0M663K629.9K
Non Currrent Assets Other20.3M17.6M6.6M4.2M63K59.9K
Other Assets6.3M10.9M4.7M831K955.7K907.9K
Cash And Short Term Investments4.8M14.5M81.3M60.8M23.9M45.9M
Net Receivables1.1M865K1.2M513K233K221.4K
Common Stock Shares Outstanding14.5M24.0M163.4M12.2M13.0M12.3M
Short Term Investments1.1K2.4M53.9M39.7M17.9M25.4M
Liabilities And Stockholders Equity25.8M32.8M91.5M66.8M26.3M24.9M
Non Current Liabilities Total52.0M54.5M35.2M38.6M19.1M31.1M
Capital Surpluse94.2M203.3M208.5M235.9M271.3M173.8M
Other Current Assets6.9M6.0M717K1.1M1.4M2.9M
Other Stockholder Equity208.5M235.9M426.9M451.2M454.8M291.9M
Total Liab52.0M83.4M41.3M38.8M32.7M39.3M
Total Current Assets4.8M14.5M81.3M60.8M25.6M47.0M
Common Stock149K494K1.8M126K135K128.3K
Property Plant And Equipment Net572K421K91K69K600K365.7K
Net Invested Capital(12.8M)(8.2M)24.9M56.5M12.6M22.6M
Property Plant And Equipment Gross7.7M421K377K353K366K347.7K
Non Current Liabilities Other7.4M19.2M10.3M1.3M188K178.6K
Net Working Capital(25.3M)(20.2M)75.3M53.4M12.1M11.5M
Property Plant Equipment7.7M421K91K1.8M1.7M1.5M
Short Long Term Debt Total13.4M35.9M24.9M28.5M19.0M24.9M
Current Deferred Revenue12.7M(7.3M)(2.5M)(332K)(298.8K)(283.9K)
Long Term Debt7.6M22.5M24.9M28.5M19.0M21.2M
Inventory(8.0M)(3.7M)(3.1M)(1.9M)(2.1M)(2.2M)
Capital Stock149K494K1.8M126K135K128.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.76)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.73)
Return On Equity
(5.56)
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.